A stock that doubled its earnings and raised ₦21 billion in fresh capital should attract heavy trading interest on the exchange.

Fidson Healthcare did not attract that interest on September 23, 2026, when the NGX hit a record market capitalization and processed 1.59 billion shares. Fidson traded just 12 shares that session and closed flat at ₦80.00, down 41% from its 52-week high of ₦136.50.

For a company growing this fast, that kind of trading silence deserves a closer look from anyone following NGX pharma stocks.

Fidson’s 12-share session came on a record day for the NGX

The contrast between Fidson’s trading activity and the broader market on September 23 could not have been sharper or more revealing. The NGX All-Share Index rose 0.23% to close at 251,191.02, while total market capitalization hit a record ₦163 trillion, Nairametrics reported.

Fidelity Bank alone drew 170.72 million shares across 714 deals that session, while Dangote Sugar moved 36.49 million shares, the Nairametrics report noted. Fidson’s 12 shares represented a fraction so small it barely qualifies as meaningful participation in the session.

Caricature image of Fidelity Bank building

The stock’s trailing price-to-earnings ratio sits at 124.33 times based on its most recent interim earnings, reflecting a price that has fallen faster than earnings growth, the NGX Daily Official List showed.

Fidson’s earnings growth tells the opposite story of its share price

Fidson Healthcare is not in decline, and its financials over the past 18 months reinforce that point with hard numbers. Revenue for the first half of 2026 reached ₦74.48 billion, an 18.9% year-over-year increase, while profit after tax climbed 28.16% to ₦7.72 billion, Nairametrics reported.

Full-year 2025 results were even stronger, with profit after tax surging 124.68% to ₦9.88 billion on revenue of ₦119.06 billion, Stock Analysis data confirmed. The company declared an annual dividend of ₦1.50 per share, with the ex-dividend date falling on April 15, 2026.

Earlier in 2026, Fidson completed a ₦21 billion rights issue that closed at a 117% subscription rate on the exchange. CardinalStone Partners, which served as financial adviser and issuing house, described the transaction as clear evidence of strong investor confidence in the company.

Thin trading volumes pose a broader risk for NGX pharma investors

Fidson’s trading drought is not an isolated event, and the structural factors behind it affect the entire NGX healthcare sector every session. May & Baker closed at ₦40.60 on September 23 and moved only 20 shares, while Neimeth traded 444 shares, the Daily Official List showed.

Caricature image of May & Baker building

Qudus Adebara, a research analyst at DLM Capital Group, reviewed Fidson’s recent earnings and flagged the liquidity tension underneath the company’s strong growth trajectory.

“Fidson Healthcare Plc delivered a strong Q1 2026 performance, with impressive revenue and profit growth. While rising receivables and declining liquidity warrant attention, the company’s expansion strategy and improving margins position it for sustained growth,” Adebara wrote in his assessment of the company.

That tension between strong fundamentals and thin trading activity is exactly what market analysts have flagged across the broader exchange. Adebola Onagoruwa, former president of the Chartered Institute of Stockbrokers, has argued that concentrated ownership and low free-float levels create structural liquidity constraints, Blueprint reported.

Fidson Healthcare: key data snapshot

Fidson’s volume gap could widen before it narrows

The additional 600 million shares from the rights issue were listed on the NGX on June 2, 2026, bringing total outstanding shares to 3 billion, Business Post reported. More shares outstanding should, in theory, create a much deeper pool of tradable equity for investors and improve daily liquidity.

Whether that added supply reaches the secondary market depends largely on how tightly existing shareholders hold their positions going forward. A stock with growing earnings, a freshly expanded share base, and a dividend yield near 1.88% at the session closing price should attract regular interest from institutional allocators.

The gap between what Fidson earns and how little it trades on any given session remains one of the most striking disconnects on the NGX. You do not need to own this stock to recognize that a 12-share session for a ₦240 billion company is a signal worth tracking.